Investigating the effects of Silymarin in the treatment of neonatal jaundice

Phase 3

Recruiting

• Conditions: eonatal jaundice.; Neonatal jaundice, unspecified; P59.9

• Registration Number: IRCT20211122053144N1
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 11 January 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Term neonates who have the AAP criteria for the treatment of hyperbilirubinemia with phototherapy
Healthy term neonates who have jaundice from the 2nd to the 10th day of birth and need phototherapy

Exclusion Criteria

Neonates with bilirubin level in range of blood exchange
The neonate or mother has received phenobarbital
Neonates with dehydration, sepsis, pneumonia, anemia, severe weight loss, hypoglycemia, renal failure, heart failure, possible hemolytic or inherited hemolytic disease, neonates with conjugated hyperbilirubinemia, neonates with G6PD, ABO or Rh incompatibility
Neonates with a history of jaundice medication from two days before

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum bilirubin. Timepoint: 24,48 and 72 hours after starting phototherapy. Method of measurement: bilirubin kit.